Core Scientific has experienced significant financial distress with a substantial net loss of $1.315 billion and negative total equity of $820.18 million, despite generating $510.672 million in revenue. The discrepancy between assets and liabilities is concerning, though a strong cash flow of $767.271 million suggests some liquidity. The recent uptick in stock price and trading volume needs careful scrutiny against the backdrop of poor financial health.